ReviewRadiology. Imaging cancer2025
Imaging Cancer-associated Cachexia: Utilizing Clinical Imaging Modalities for Early Diagnosis.
Review in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reliable Radiologic Skeletal Muscle Area Assessment-A Biomarker for Cancer Cachexia Diagnosis.Cells · 2026Article
- Role of mitochondrial dysfunction in muscle wasting in cancer cachexia: a narrative review.Journal of translational medicine · 2026Review
- Tumor-Derived Polyamines Initiate Fat Wasting in Cancer Cachexia.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated cachexia (CAC) is a prevalent condition that accelerates cancer progression and heightens treatment-related adverse effects in patients by affecting multiple organ systems. Despite the profound impact of CAC on clinical management and treatment outcomes of patients with cancer, the current understanding of mechanisms associated with the condition, as well as the tools necessary for early diagnosis, are limited. Currently, the clinical diagnosis of CAC relies on weight change-based assessments, which have limited sensitivity and cannot identify patients at risk for CAC. In this context, noninvasive imaging-based biomarkers, such as the composition and properties of adipose and muscle tissues, may allow for diagnosis of CAC before substantial weight loss occurs. Such early detection can potentially enable more timely and effective interventions. Furthermore, imaging allows for quantitative assessment of CAC, enabling monitoring of prognosis and treatment response. This article reviews current applications and future developments of imaging techniques, particularly those employed in current clinical radiology, that can reveal diagnostic information and facilitate early detection of CAC and quantitative evaluation of associated metabolic alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.